RARA CRAFT DATABASE for FDA Medical Devices
510(k)K200530

FDA DEVICE FACTS

AMICUS Separator System

Fresenius Kabi AG

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATESeptember 11, 2020PRODUCT CODEGKT

Indications for use

Depending on the AMICUS Separator System disposable used in the therapeutic apheresis procedure, the AMICUS Separator System has been cleared for the following: The AMICUS Separator System is an automated blood cell separator indicated to perform therapeutic plasma exchange (TPE). (K111702) The AMICUS Exchange Kit is indicated for use in therapeutic plasma exchange (TPE). The kit is for use with the AMICUS separator. (K111702) The AMICUS Separator System is an automated blood component separator indicated to perform red blood cell exchange (RBCX), including exchange and depletion/exchange procedures, for the transfusion management of sickle cell disease in adults and children. (K180615) The AMICUS Exchange Kit – Therapeutics is indicated for use in therapeutic plasma exchange (TPE) and red blood cell exchange (RBCX). The kit is for use with the AMICUS separator. (K111702, K180615) The waste transfer set is indicated for use in red blood cell exchange (RBCX). The set is for use with the AMICUS separator. (K180615) The Blood Component Filter Set with Vented Spike and Luer Adapter is indicated for the administration of blood and blood components during a therapeutic plasma exchange (TPE) or red blood cell exchange (RBCX) therapeutic apheresis procedure. The set is for use with the AMICUS separator. (K111702, K180615) The AMICUS Separator System is an automated blood cell separator indicated for the collection of blood components and mononuclear cells. Depending on the AMICUS Separator System apheresis kit used in the collection of products, the AMICUS Separator System has been cleared to collect:

• Platelets Pheresis, Leukocytes Reduced (single, double, or triple units) (BK960005, BK990009)

• Platelets Pheresis, Leukocytes Reduced, Platelet Additive Solution (InterSol) (single, double or triple units) (BK090065)

• Red Blood Cells, Leukocytes Reduced (by apheresis) (BK000039)

• Mononuclear Cells (BK000047)

• Plasma (BK960005, BK120041) ○ Fresh Frozen Plasma

▪ Must be prepared and placed in a freezer at -18° C or colder within eight hours after phlebotomy. ○ Plasma Frozen Within 24 Hours After Phlebotomy (PF24)

▪ Must be stored at 1-6°C within eight hours after phlebotomy and placed in a freezer at -18° C or colder within 24 hours after phlebotomy.

▪ Indicated for replacement of non-labile clotting factors. This product is not equivalent to Fresh Frozen Plasma. ○ Plasma Frozen Within 24 Hours After Phlebotomy (PF24) Held at Room Temperature Up to 24 Hours After Phlebotomy (PF24RT24)

▪ Can be stored at room temperature for up to 24 hours after phlebotomy. Product must be placed in a freezer at -18° C or colder within 24 hours after phlebotomy.

▪ Indicated for replacement of non-labile clotting factors. This product is not equivalent to Fresh Frozen Plasma. ○ Source Plasma The device is designed to collect products while maintaining an extracorporeal volume at or below 10.5ml/kg and a donor post-platelet count greater than or equal to 100,000 platelets/microliter. (BK960005 and BK990009) Platelet Pheresis (single, double, or triple units) may be manufactured from products that do not meet leukocyte reduction product standards. This does not apply to Platelet Pheresis, Platelet Additive Solution (InterSol) (single, double, or triple units). (BK990009 and BK090065) The AMICUS platelet storage container is cleared to store Platelets Pheresis, Leukocytes Reduced in 100% plasma for up to seven days. Additionally, for platelet units stored past five days and through seven days, every product must be tested with a bacterial device cleared by FDA and labeled as a “safety measure.” (BK050038 and BK150242) Technological Comparison as Compared to the Predicate Device The technological characteristics of the AMICUS separator are standardized across procedures and remain the same as the predicate AMICUS device. This includes the centrifuge system, separation technology, fluid control system, safety management system (including safety sensors and alerts) and anticoagulant management system which monitors and controls the delivery of anticoagulant solution based on operator parameters. There is no change in the fundamental scientific technology or principles of operation. The physical design of the AMICUS instrument includes three main areas of operation (touch screen, top panel and centrifuge) that have the same technological characteristics as the predicate AMICUS device. There is no change in physical dimensions, manufacturing facility or processes. The performance specifications and data management capabilities remain the same as the cleared AMICUS device. The AMICUS apheresis kits are unaffected and remain the same as the currently cleared kits including design, labeling, materials and manufacturing methods. A comparison of the technological characteristics between the predicate device and the subject device is provided in the table below. Element Predicate Device Proposed Device

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 24, 2026